News Articles for "Valeant"
-
Valeant Pharma plans $1.75B stock offering
Canadian drugmaker Valeant Pharmaceuticals International Inc. said Monday it will sell $1.75 billion in stock to help fund its acquisition of Bausch + Lom...
read more -
Tiffany, Tesla, Michael Kors are big movers
Stocks that moved substantially or traded heavily Tuesday on the New York Stock Exchange and the Nasdaq Stock Market: NYSE Tiffany & Co., up $3.01 at $79....
read more
Search Results for "Valeant"
 |
|
| Type | Public company |
|---|---|
| Traded as | NYSE: VRX TSX: VRX S&P/TSX 60 component |
| Industry | Pharmaceutical industry |
| Founded | 1960 |
| Headquarters | Laval, Québec, Canada |
| Key people | J. Michael Pearson (Chairman & CEO) |
| Products | Cesamet (nabilone) Efudex Mestinon Diastat Ribavirin (licensed to Schering Plough) |
| Revenue | $3.5 billion (2012)[1] |
| Website | www.valeant.com |
